5.92
+0.73(+14.07%)
Currency In USD
| Previous Close | 5.19 |
| Open | 5.38 |
| Day High | 5.97 |
| Day Low | 5.36 |
| 52-Week High | 7.37 |
| 52-Week Low | 2.41 |
| Volume | 1.54M |
| Average Volume | 1.15M |
| Market Cap | 461.22M |
| PE | -2.39 |
| EPS | -2.48 |
| Moving Average 50 Days | 5.36 |
| Moving Average 200 Days | 4.9 |
| Change | 0.73 |
If you invested $1000 in Solid Biosciences Inc. (SLDB) since IPO date, it would be worth $17.45 as of December 04, 2025 at a share price of $5.92. Whereas If you bought $1000 worth of Solid Biosciences Inc. (SLDB) shares 5 years ago, it would be worth $108.72 as of December 04, 2025 at a share price of $5.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
GlobeNewswire Inc.
Dec 01, 2025 1:00 PM GMT
– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia – – FALCON Phase 1b clinical trial participant screening underway – CHARLEST
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
- Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) -- AAV-SLB101 has been generally well t
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
- Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines - - New Innovative Licensing and Access Pathway (ILAP) designation provides unique, end-to-end regulatory access pat